European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management.
作者信息
Raffaelli Marco, Voloudakis Nikolaos, Barczynski Marcin, Brauckhoff Katrin, Durante Cosimo, Gomez-Ramirez Joaquin, Koutelidakis Ioannis, Lorenz Kerstin, Makay Ozer, Materazzi Gabriele, Pandev Rumen, Randolph Gregory W, Tolley Neil, Vriens Menno, Musholt Thomas
机构信息
UOC Chirurgia Endocrina e Metabolica, Centro Dipartimentale di Chirurgia Endocrina e dell'Obesità, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Centro di Ricerca in Chirurgia delle Ghiandole Endocrine e dell'Obesità (CREO), Università Cattolica del Sacro Cuore, Rome, Italy.
出版信息
Br J Surg. 2024 Aug 2;111(8). doi: 10.1093/bjs/znae199.
Abstract
摘要
相似文献
1
European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management.欧洲内分泌外科学会（ESES）关于晚期甲状腺癌的共识声明：定义与管理
Br J Surg. 2024 Aug 2;111(8). doi: 10.1093/bjs/znae199.
2
Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).遗传性 C 细胞疾病基因携带者甲状腺手术的时机和范围——欧洲内分泌外科学会（ESES）的共识声明。
Langenbecks Arch Surg. 2014 Feb;399(2):185-97. doi: 10.1007/s00423-013-1139-5. Epub 2013 Dec 3.
3
Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES).多灶性甲状腺乳头状癌——欧洲内分泌外科学会（ESES）的共识报告。
Langenbecks Arch Surg. 2014 Feb;399(2):141-54. doi: 10.1007/s00423-013-1145-7. Epub 2013 Nov 22.
4
Consensus statement of the European Society of Endocrine Surgeons (ESES) on advanced parathyroid cancer: definitions and management.欧洲内分泌外科学会（ESES）关于晚期甲状旁腺癌的共识声明：定义与管理
Br J Surg. 2024 May 3;111(5). doi: 10.1093/bjs/znae108.
5
[European consensus on the management of patients with differentiated carcinoma of the thyroid from follicular epithelium].[欧洲关于滤泡上皮来源的分化型甲状腺癌患者管理的共识]
Vestn Khir Im I I Grek. 2008;167(1):52-6.
6
Indications and extent of central neck dissection for papillary thyroid cancer: An American Head and Neck Society Consensus Statement.甲状腺乳头状癌中央区颈清扫术的适应证及范围：美国头颈学会共识声明
Head Neck. 2017 Jul;39(7):1269-1279. doi: 10.1002/hed.24715. Epub 2017 Apr 27.
7
The European Society of Endocrine Surgeons perspective of thyroid cancer surgery: an evidence-based approach.欧洲内分泌外科学会关于甲状腺癌手术的观点：循证方法
Langenbecks Arch Surg. 2014 Feb;399(2):135-9. doi: 10.1007/s00423-013-1157-3. Epub 2014 Feb 7.
8
Revisiting the guidelines issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: a gradual move towards consensus between Japanese and western practice in the management of thyroid carcinoma.重新审视日本甲状腺外科医生协会和日本内分泌外科医生协会发布的指南：在甲状腺癌管理方面，日本与西方实践正逐步走向共识。
World J Surg. 2014 Aug;38(8):2002-10. doi: 10.1007/s00268-014-2498-y.
9
Familial nonmedullary thyroid carcinoma-clinical relevance and prognosis. A European multicenter study. ESES Vienna presentation.家族性非髓样甲状腺癌——临床相关性和预后。一项欧洲多中心研究。ESES 维也纳报告。
Langenbecks Arch Surg. 2010 Sep;395(7):851-8. doi: 10.1007/s00423-010-0696-0. Epub 2010 Aug 5.
10
Comprehensive management of recurrent thyroid cancer: An American Head and Neck Society consensus statement: AHNS consensus statement.复发性甲状腺癌的综合管理：美国头颈学会共识声明：AHNS共识声明
Head Neck. 2016 Dec;38(12):1862-1869. doi: 10.1002/hed.24513. Epub 2016 Sep 22.
引用本文的文献
1
The impact of immersive virtual reality training in thyroid surgery: a prospective randomized controlled trial.沉浸式虚拟现实训练对甲状腺手术的影响：一项前瞻性随机对照试验。
Updates Surg. 2025 Aug 29. doi: 10.1007/s13304-025-02387-8.
2
Role of Volumetric Modulated Arc radioTherapy (VMAT) in the adjuvant treatment of locally advanced differentiated thyroid cancer: single institution experience.容积调强弧形放疗（VMAT）在局部晚期分化型甲状腺癌辅助治疗中的作用：单机构经验
J Endocrinol Invest. 2025 Jul 9. doi: 10.1007/s40618-025-02644-y.
3
Presidential address: current state and future prospects of the European Society of Endocrine Surgeons.主席致辞：欧洲内分泌外科学会的现状与未来展望
Updates Surg. 2025 May 8. doi: 10.1007/s13304-025-02249-3.
4
Intraoperative nerve monitoring in thyroid and parathyroid surgery: a decade of Italian practice.甲状腺和甲状旁腺手术中的术中神经监测：意大利十年实践
Updates Surg. 2025 Apr 1. doi: 10.1007/s13304-025-02157-6.
5
The potential role of neoadjuvant treatment in thyroid cancers in the era of kinase inhibitors: a narrative review.激酶抑制剂时代新辅助治疗在甲状腺癌中的潜在作用：一篇叙述性综述。
Endocrine. 2025 Feb 4. doi: 10.1007/s12020-025-04182-2.
6
Surgery for Locally Invasive Thyroid Cancer: Balancing Morbidity with Long Term Outcomes.局部侵袭性甲状腺癌的手术治疗：权衡发病率与长期预后
Ann Surg Oncol. 2025 Feb;32(2):632-633. doi: 10.1245/s10434-024-16541-w. Epub 2024 Nov 18.
7
Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma.局部晚期甲状腺癌的新辅助治疗
J Clin Med. 2024 Sep 27;13(19):5769. doi: 10.3390/jcm13195769.
本文引用的文献
1
Return of Vocal Fold Motion and Surgical Preservation of Invaded Recurrent Laryngeal Nerves After the Use of Neoadjuvant Therapy in Patients Presenting with Advanced Thyroid Cancer and Vocal Fold Paralysis: The Lazarus Effect.新辅助治疗后晚期甲状腺癌伴声带麻痹患者声带运动恢复及受侵喉返神经的手术保留：拉撒路效应
Thyroid. 2023 Oct;33(10):1259-1263. doi: 10.1089/thy.2023.0136.
2
Neoadjuvant tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a single centre case series.局部晚期分化型甲状腺癌的新辅助酪氨酸激酶抑制剂治疗：单中心病例系列。
J Laryngol Otol. 2023 Nov;137(11):1237-1243. doi: 10.1017/S0022215123000506. Epub 2023 Mar 22.
3
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.KEYNOTE-158 期研究中帕博利珠单抗单药治疗晚期甲状腺癌患者的疗效和安全性。
Cancer. 2023 Apr 15;129(8):1195-1204. doi: 10.1002/cncr.34657. Epub 2023 Feb 7.
4
Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.基于突变的短期“新辅助”治疗可使 IVB 和 C 期间变性甲状腺癌具有可切除性。
Eur Arch Otorhinolaryngol. 2023 Mar;280(3):1509-1518. doi: 10.1007/s00405-023-07827-y. Epub 2023 Jan 13.
5
Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancer.晚期甲状腺癌患者联合颈部和经胸手术入路的临床结局
Head Neck. 2023 Mar;45(3):547-554. doi: 10.1002/hed.27260. Epub 2022 Dec 16.
6
Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series.用于甲状腺髓样癌的新辅助选择性RET抑制剂：病例系列
Thyroid. 2023 Jan;33(1):129-132. doi: 10.1089/thy.2022.0506.
7
Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective.进展性放射性碘难治性甲状腺癌的管理：当前观点
Cancer Manag Res. 2022 Oct 21;14:3047-3062. doi: 10.2147/CMAR.S340967. eCollection 2022.
8
Impact of Local Control on Clinical Course in Stage IVC Anaplastic Thyroid Carcinoma.局部控制对 IVC 期间变性甲状腺癌临床病程的影响。
World J Surg. 2022 Dec;46(12):3034-3042. doi: 10.1007/s00268-022-06739-y. Epub 2022 Sep 20.
9
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve -mutant medullary thyroid cancer.LIBRETTO-531 研究：塞普替尼在初治多激酶抑制剂-naïve 型突变型甲状腺髓样癌中的 III 期研究。
Future Oncol. 2022 Sep;18(28):3143-3150. doi: 10.2217/fon-2022-0657. Epub 2022 Aug 15.
10
Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.手术对转移型间变性甲状腺癌原发肿瘤的作用：汇总分析和基于 SEER 的研究。
J Cancer Res Clin Oncol. 2023 Jul;149(7):3527-3547. doi: 10.1007/s00432-022-04223-7. Epub 2022 Aug 12.
Zotero 插件